---
pmid: '32395830'
title: Mutations in GET4 disrupt the transmembrane domain recognition complex pathway.
authors:
- Tambe MA
- Ng BG
- Shimada S
- Wolfe LA
- Adams DR
- Undiagnosed Diseases Network
- Gahl WA
- Bamshad MJ
- Nickerson DA
- Malicdan MCV
- Freeze HH
journal: J Inherit Metab Dis
year: '2020'
full_text_available: false
pmcid: PMC7508799
doi: 10.1002/jimd.12249
---

# Mutations in GET4 disrupt the transmembrane domain recognition complex pathway.
**Authors:** Tambe MA, Ng BG, Shimada S, Wolfe LA, Adams DR, Undiagnosed Diseases Network, Gahl WA, Bamshad MJ, Nickerson DA, Malicdan MCV, Freeze HH
**Journal:** J Inherit Metab Dis (2020)
**DOI:** [10.1002/jimd.12249](https://doi.org/10.1002/jimd.12249)
**PMC:** [PMC7508799](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508799/)

## Abstract

1. J Inherit Metab Dis. 2020 Sep;43(5):1037-1045. doi: 10.1002/jimd.12249. Epub 
2020 Jun 3.

Mutations in GET4 disrupt the transmembrane domain recognition complex pathway.

Tambe MA(1), Ng BG(1), Shimada S(2), Wolfe LA(2), Adams DR(2)(3); Undiagnosed 
Diseases Network(4); Gahl WA(2)(3), Bamshad MJ(5)(6), Nickerson DA(6), Malicdan 
MCV(2)(3), Freeze HH(1).

Author information:
(1)Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, 
La Jolla, California, USA.
(2)Undiagnosed Diseases Program, National Human Genome Research Institute 
(NHGRI), National Institutes of Health (NIH), Bethesda, Maryland, USA.
(3)Section of Human Biochemical Genetics, Medical Genetics Branch, NHGRI, NIH, 
Bethesda, Maryland, USA.
(4)Common Fund, Office of the Director, NIH, Bethesda, Maryland, USA.
(5)Department of Pediatrics, University of Washington Seattle, Seattle, 
Washington, USA.
(6)Department of Genome Sciences, University of Washington Seattle, University 
of Washington Centre for Mendelian Genomics, Seattle, Washington, USA.

The transmembrane domain recognition complex (TRC) targets cytoplasmic 
C-terminal tail-anchored (TA) proteins to their respective membranes in the 
endoplasmic reticulum (ER), Golgi, and mitochondria. It is composed of three 
proteins, GET4, BAG6, and GET5. We identified an individual with compound 
heterozygous missense variants (p.Arg122His, p.Ile279Met) in GET4 that reduced 
all three TRC proteins by 70% to 90% in his fibroblasts, suggesting a possible 
defect in TA protein targeting. He presented with global developmental delay, 
intellectual disabilities, seizures, facial dysmorphism, and delayed bone age. 
We found the TA protein, syntaxin 5, is poorly targeted to Golgi membranes 
compared to normal controls. Since GET4 regulates ER to Golgi transport, we 
hypothesized that such transport would be disrupted in his fibroblasts, and 
discovered that retrograde (but not anterograde) transport was significantly 
reduced. Despite reduction in the three TRC proteins, their mRNA levels were 
unchanged, suggesting increased degradation in patient fibroblasts. Treating 
fibroblasts with the FDA-approved proteasome inhibitor, bortezomib (10 nM), 
restored syntaxin 5 localization and nearly normalized the levels of all three 
TRC proteins. Our study identifies the first individual with GET4 mutations.

Â© 2020 SSIEM.

DOI: 10.1002/jimd.12249
PMCID: PMC7508799
PMID: 32395830 [Indexed for MEDLINE]

Conflict of interest statement: CONFLICT OF INTEREST Mitali A. Tambe, Bobby G. 
Ng, Shino Shimada, Lynne A. Wolfe, David R. Adams, Undiagnosed Diseases Network, 
William A. Gahl, University of Washington Center for Mendelian Genomics, May 
C.V. Malicdan and Hudson H. Freeze declare that they have no conflict of 
interest.
